Cancer alertness in patients with rheumatic diseases
https://doi.org/10.14412/1996-7012-2020-2-117-122
Abstract
The processes that vary in nature and underlie the pathogenesis of malignant neoplasms (MNs) and immune-mediated inflammatory rheumatic diseases (RDs) share just the same some common features. Thus, many early-stage neoplasias can mask autoimmune diseases, requiring that physicians of various specialties should comply with the principle of cancer alertness. When specific cancer treatments (immunotherapy, cytostatic therapy, radiotherapy) are performed, there may be certain rheumatic syndromes (arthritis, myalgia, serositis, etc.) that require a differential diagnosis. At the same time, the course of a number of RDs (rheumatoid arthritis, Sjögren's syndrome, and polymyositis) can be accompanied by the development of MNs, which is relevant for real clinical practice and calls for further investigation.
The community of etiological factors and a genetic predisposition in the development of RDs and MNs remain to be of no less importance. At the same time, therapists should pay attention to the presence of rheumatic masks in many MNs, which undoubtedly prolongs the time between onset of the first symptoms and correct diagnosis.
About the Authors
A. S. Sycheva
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Russian Federation
Aleksandra Sergeevna Sycheva
Department of Therapy, Clinical Pharmacology, and Emergency Medicine
20, Delegatskaya St., Build. 1, Moscow 127473
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Rheumatology, Russian Medical Academy of Continuing Professional Education
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya St., Build. 1, Moscow 125993
A. L. Vertkin
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Therapy, Clinical Pharmacology, and Emergency Medicine
20, Delegatskaya St., Build. 1, Moscow 127473
D. A. Khlanta
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Therapy, Clinical Pharmacology, and Emergency Medicine
20, Delegatskaya St., Build. 1, Moscow 127473
References
1. Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol. 2016 Jan; 174(1):158-64.
2. Andras C, Levente B, Nagy-Vincze M, et al. Retrospective Analysis of CancerAssociated Myositis Patients over the Past 3 Decades in a Hungarian Myositis Cohort. Pathol Oncol Res. 2019 Oct 23. doi: 10.1007/s12253-019-00756-4. [Epub ahead of print].
3. Rahat MA, Shakya J. Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease. Mediators Inflamm. 2016;2016:4375120. doi: 10.1155/2016/4375120. Epub 2016 Feb 22.
4. Bellan M, Boggio E, Sola D, et al. Association between rheumatic diseases and cancer: results from a clinical practice cohort study. Intern Emerg Med. 2017 Aug;12(5): 621-7. doi: 10.1007/s11739-017-1626-8. Epub 2017 Feb 8.
5. Kleinert S, La Rosee P, Krü ger K. Rheumatoid symptoms in patients with hematologic neoplasms. Z Rheumatol. 2017 Oct;76(Suppl 2):38-45. doi: 10.1007/s00393017-0338-9
6. Grignano E, Jachiet V, Fenaux P, et al. Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol. 2018 Nov;97(11):2015-23. doi: 10.1007/s00277-018-3472-9. Epub 2018 Aug 8.
7. Ceribelli A, Isailovic N, De Santis M, et al. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol. 2017 Feb;36(2): 469-75. doi: 10.1007/s10067-016-3453-0. Epub 2016 Oct 20.
8. Ahumada Pina H, Fuentes Cabrera L, Selame Glena R, et al. Dermatomyositis as the first manifestation of small cell carcinoma: case report and literature review. Medwave. 2016 Nov 15;16(10):e6609. doi: 10.5867/medwave.2016.10.6609
9. Cho HG, Kuo KY, Xiao K, et al. Azathioprine and risk of multiple keratinocyte cancers. J Am Acad Dermatol. 2018 Jan;78(1):27-28.e1. doi: 10.1016/j.jaad.2017.09.063. Epub 2017 Oct 5.
10. Khan S, Jain M, Mathur V, Feroz SM. Chronic Inflammation and Cancer: Paradigm on Tumor Progression, Metastasis and Therapeutic Intervention. Gulf J Oncolog. 2016 Jan;1(20):86-93.
11. Landgren AM, Landgren O, Gridley G, et al. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer. 2011 Mar 15;117(6):1163-71. doi: 10.1002/cncr.25524. Epub 2010 Nov 2.
12. Correia NC, Girio A, Antunes I, et al. The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer. 2014 Jan;50(1):216-25. doi: 10.1016/j.ejca.2013.08.017. Epub 2013 Sep 19.
13. Maria ATJ, Partouche L, Goulabchand R, et al. Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors. Front Immunol. 2019 Jan 10;9:3112. doi: 10.3389/fimmu.2018.03112. eCollection 2018.
14. Okogbaa J, Batiste L. Dermatomyositis: An Acute Flare and Current Treatments. Clin Med Insights Case Rep. 2019 Jun 18;12: 1179547619855370. doi: 10.1177/1179547619855370. eCollection 2019.
15. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 Dec;76(12):1955-64. doi: 10.1136/annrheumdis-2017-211468
16. Leatham H, Schadt C, Chisolm S, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Medicine (Baltimore). 2018 Jan;97(2):e9639. doi: 10.1097/MD.0000000000009639
17. Di Rollo D, Abeni D, Tracanna M, et al. Cancer risk in dermatomyositis: a systematic review of the literature. G Ital Dermatol Venereol. 2014 Oct;149(5):525-37. Epub 2014 Jun 30.
18. Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of Malignancy in Dermatomyositis and Polymyositis. J Cutan Med Surg. 2017 Mar/Apr;21(2):131-6. doi: 10.1177/1203475416665601. Epub 2016 Aug 20.
19. Fang YF, Wu YJ, Kuo CF, et al. Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin Rheumatol. 2016 Aug;35(8):1977-84. doi: 10.1007/s10067-016-3296-8. Epub 2016 May 23.
20. Dobloug GC, Garen T, Brunborg C, et al. Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort. Semin Arthritis Rheum. 2015 Dec;45(3):301-8. doi: 10.1016/j.semarthrit.2015.06.005. Epub 2015 Jun 17.
21. Yamashita H, Ueda Y, Ozaki T, et al. Characteristics of 10 patients with paraneoplastic rheumatologic musculoskeletal manifestations. Mod Rheumatol. 2014 May;24(3): 492-8. doi: 10.3109/14397595.2013.843762. Epub 2013 Nov 5.
22. Batut RC, Juchet H, Tubery M, et al. ArletDermatopolymyosite et cancer: etude retrospective de 12 cas parmi une cohorte de 50. Evolution et facteurs predictifs. Rev Med Interne. 1998;19(Suppl. 1):120.
23. Yu KH, Kuo CF, Huang LH, et al. Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan. Medicine (Baltimore). 2016 May;95(18):e3540. doi: 10.1097/MD.0000000000003540
24. Leipe J, Schulze-Koops H. Paraneoplastic syndromes in rheumatology. Internist (Berl). 2018 Feb;59(2):145-50. doi: 10.1007/s00108-017-0376-z.
25. Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017 Oct;16(10):1049-57. doi: 10.1016/j.autrev.2017.07.022. Epub 2017 Aug 1.
26. Chakravarty SD, Markenson JA. Arthritis accompanying endocrine and metabolic disorders. In: Firestein GS, Budd RC, Gabriel SE, et al, editors. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Elsevier; 2017.
27. Machado RI, Braz Ade S, Freire EA. Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review. Rev Bras Reumatol. 2014 Mar-Apr; 54(2):131-9.
28. Brito-Zeron P, Kostov B, Fraile G, et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol. 2017 Apr 17;10(1):90. doi: 10.1186/s13045-017-0464-5
29. Mercer LK, Regierer AC, Mariette X, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis. 2017 Dec;76(12): 2025-30. doi: 10.1136/annrheumdis-2017211623. Epub 2017 Aug 19.
30. Hellgren K, Baecklund E, Backlin C, et al. Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased? Arthritis Rheum. 2017 Apr; 69(4):700-8. doi: 10.1002/art.40017.
31. Lee H. The Risk of Malignancy in Korean Patients with Rheumatoid Arthritis. Yonsei Med J. 2019 Feb;60(2):223-9. doi: 10.3349/ymj.2019.60.2.223
32. Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013 Apr 8;346:f1939. doi: 10.1136/bmj.f1939
33. Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancerclinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018 Mar;77(3): 393-8. doi: 10.1136/annrheumdis-2017212257. Epub 2017 Nov 16.
34. Yates WB, Vajdic CM, Na R, et al. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study. Ophthalmology. 2015 Feb;122(2): 265-73. doi: 10.1016/j.ophtha.2014.08.024. Epub 2014 Oct 11.
35. Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factoralpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.
36. Liu Y, Fan W, Chen H, et al. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials. Asian Pac J Cancer Prev. 2014;15(8):3403-10.
37. Mercer LK, Galloway JB, Lunt M, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2017 Mar;76(3):497-503. doi: 10.1136/annrheumdis-2016-209389. Epub 2016 Aug 8.
38. Bonovas S, Minozzi S, Lytras T et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016 Dec;15(sup1):35-54.
39. Van der Heijde D, Zack D, Wajdula J, et al. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis. Scand J Rheumatol. 2014;43(1):49-53. doi: 10.3109/03009742.2013.834961. Epub 2013 Nov 1.
40. Wells AF, Curtis JR, Betts KA, et al. Systematic Literature Review and Metaanalysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. Clin Ther. 2017 Aug;39(8):1680-94.e2. doi: 10.1016/j.clinthera.2017.06.013. Epub 2017 Jul 20.
41. Swierkot J, Lewandowicz-Uszynska A, Bogunia-Kubik K. Paraneoplastic syndromes and rheumatic diseases. Postepy Hig Med Dosw (Online). 2014 Jul 4;68:944-54.
Review
For citations:
Sycheva AS, Lila AM, Vertkin AL, Khlanta DA. Cancer alertness in patients with rheumatic diseases. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(2):117-122. (In Russ.) https://doi.org/10.14412/1996-7012-2020-2-117-122
Views:
979
Email this article 